BRASTER S.A. signed with Warsaw University of Technology – Institute of Electronic Systems (EiTI) agreement concerning conduction of third phase of works, which aim is to improve effectivity of systems for automatic interpretation of thermographic examination, and also to develop system prototype for differential interpretation of historic tests of the same woman.

In result of almost yearlong cooperation with PW – The Faculty of Electronics and Information Technology (EiTI) - arise fully functioning prototype of system for automatic interpretation of thermographic images. Further development of this project has for it success a strategical meaning – optimisation of system prototype will cause increase of diagnostic effectivity (sensitivity + specificity). Moreover within this phase the training set (base of thermographs, used by application to “learn” how to recognise pathology) will increase, also the prototype of system for differential interpretation of historic tests of the same woman will be created.

"We consistently pursue our strategy. Before the end of the year we will have an efficient, optimized system for the automatic detection of lesions. At the same time, we are beginning work on the app which distinguishes Braster from other diagnostic methods – I am talking about the function comparing the subsequent examination results to identify the changes, which will potentially allow for the identification of the threats at a very early stage of development." – says Marcin Halicki, President of the Board of BRASTER S.A..

The work on modification of dedicated algorithms is set to significantly improve the parameters of the data interpretation system (sensitivity and specificity). The aim of the above activities is to receive sensitivity and specificity of 80% and above.

The version of the system developed under this project will be used in a clinical trial on around 3,000 women under the INNOMED project, implemented jointly with the Collegium Medicum of the Jagiellonian University.

In June 2015, BRASTER moved its listing from NewConnect to the main Warsaw Stock Exchange (WSE) market. Before its debut on the WSE, the company held a successful public offering, as a result of which it obtained PLN 39 million from investors. The company will allocate the capital from the issue to financing its new development strategy to introduce the Braster device to direct sale to women in the second half of 2016. The funds will be used for building a technology line, developing the final, commercial version of the device, creating a system for the automatic interpretation of thermographic images received from the Braster device, and completing the work related to placing the product on the market.

The product will first be available on the Polish market. In 2017, its distribution in Germany and the United Kingdom is projected to begin. A year later the device will be placed on the markets of, among others, other European Union countries and the United States.